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2013 A stock market, it is Rainbow Night, reflect the Chinese macroeconomic 
situation of the blue chip is no improvement, the SSE trading volume has less than 
the Shenzhen Stock Exchange has become the norm, the stock market price earnings 
ratio, banking stocks breaking the net for the SSE traded light to provide a footnote. 
Although the Shanghai Composite Index fell to 6.75% year, but nearly 70% of the 
market value of listing Corporation has increased, there are 72% industry market 
value of listing Corporation to achieve growth, showing a structural bull market 
characteristics, these industries are high-tech, Internet, culture, consumption, 
medicine, environmental protection. In this context, as an individual investor, how 
should we choose investment targets, how to determine the listing Corporation's 
stock investment value? Following the top-down selection strategy, receives the 
value investment idea, this paper selects the medical section of the two listing 
Corporation -- Andon Medical and Shinva Medical, collect the company from 2008 
to 2012 financial and operating data, using the discount free cash flow model and 
price earnings ratio model, the valuation of the two company's stock price, in order to 
provide objective, scientific, rational basis for investors to make investment decision. 
This paper is divided into six chapters, the main problems and the significance 
of research background, the first chapter of this paper. The second chapter introduces 
the development status and trend of China's medical industry, the main problems and 
the development of the overall situation, in order to investors in the medical device 
industry to have a basic understanding of the. The third chapter is the analysis of the 
listing Corporation's business model, core competence and market prospect. The 
fourth chapter analyzes the historical financial data, and carries on the forecast to the 
main business of financial data, a comprehensive understanding of Andon Medical 
and Shinva Medical. The fifth chapter uses the discounted free cash flow and 
earnings of the valuation method of two companies, two companies estimate the 
reasonable price interval, and the valuation method of error prompt. The main 
conclusions of the sixth chapter research conclusion, including industry, business 
analysis and valuation conclusion, and according to the valuation results are given for 















After analysis, think that Andon Medical shares from the company actual 
financial performance, stock price bubble serious, and Shinva Medical growth and 
performance is stable, the current stock price is undervalued, buy and hold. At the 
same time, the author put forward some investment advice: in the current 
macro-economic background, we recommend the top-down selection strategies, first 
select the growth of clear, broad space industry. After the selected sectors, to 
determine the selection of cash performance in the industry, the future development 
of high-quality stocks. 
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